Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
For context, Wegovy costs approximately $1,350 per month at list price
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
References Massachusetts Male Aging Study A foundational longitudinal study on the prevalence and causes of vascular erectile issues in aging men
Six months after starting treatment, patients HbA1c levelsfrom a blood test that measures a persons average glucose level over the previous 8-12 weeksimproved, falling an average of 0.77%
This hormone plays a key role in regulating your appetite and blood sugar levels
US$ 27.32
US$ 29.10
US$ 25.74
US$ 20.22
